Agios PharmaceuticalsAGIO
AGIO
About: Agios Pharmaceuticals Inc is a biopharmaceutical company focused on the field of cellular metabolism to create differentiated medicines for rare diseases, with a focus on classical hematology. The company's primary focus is to develop potentially transformative small-molecule medicines. Its product candidate, Pyrukynd (mitapivat), is an activator of both wild-type and mutant pyruvate kinase enzymes, developed for the treatment of hemolytic anemias. The other drug candidates in its pipeline include Tebapivat (PK activator), being developed as a potential treatment for MDS-associated anemia and sickle cell disease, AG-181 (PAH stabilizer), AG-236, and others.
Employees: 488
0
Funds holding %
of 7,299 funds
–
Analysts bullish %
Fund manager confidence
Based on 2025 Q1 regulatory disclosures by fund managers ($100M+ AUM)
200% more funds holding in top 10
Funds holding in top 10: 1 [Q4 2024] → 3 (+2) [Q1 2025]
0.25% less ownership
Funds ownership: 104.91% [Q4 2024] → 104.66% (-0.25%) [Q1 2025]
4% less call options, than puts
Call options by funds: $10.6M | Put options by funds: $11.1M
5% less repeat investments, than reductions
Existing positions increased: 73 | Existing positions reduced: 77
8% less first-time investments, than exits
New positions opened: 37 | Existing positions closed: 40
3% less funds holding
Funds holding: 223 [Q4 2024] → 217 (-6) [Q1 2025]
11% less capital invested
Capital invested by funds: $1.97B [Q4 2024] → $1.76B (-$207M) [Q1 2025]
Research analyst outlook
1 Wall Street Analyst provided 1 year price targets over the past 3 months
Low target
$71
101%
upside
Avg. target
$71
101%
upside
High target
$71
101%
upside
1 analyst rating
1 positive
100%
0 neutral
0%
0 negative
0%
Scotiabank Greg Harrison | 101%upside $71 | Sector Outperform Maintained | 2 May 2025 |
Financial journalist opinion
Neutral
Business Wire
1 week ago
Avanzanite Announces Pan-European Partnership with Agios to Launch PYRUKYND® in Rare Blood Disorders
AMSTERDAM--(BUSINESS WIRE)-- #biotech--Avanzanite Bioscience B.V. (“Avanzanite”), a fast-growing commercial-stage specialty pharmaceutical company dedicated to bringing rare disease medicines to patients across Europe, announced today an exclusive agreement with Agios Pharmaceuticals Inc. (Nasdaq: AGIO), a Boston-based biotech company focused on the development and commercialization of rare disease medicines. Under the agreement, Avanzanite will commercialize and distribute PYRUKYND® (mitapivat) across th.
Neutral
GlobeNewsWire
2 weeks ago
Agios to Present at Goldman Sachs 46th Annual Global Healthcare Conference on June 9, 2025
Agios Pharmaceuticals, Inc. announced that its management team is scheduled to present at the Goldman Sachs Healthcare Conference on June 9 at 8:40 a.m. ET
Neutral
GlobeNewsWire
1 month ago
Agios to Highlight Pyruvate Kinase Activation Portfolio with New Data in Rare Blood Disorders at 30th EHA Congress
CAMBRIDGE, Mass., May 14, 2025 (GLOBE NEWSWIRE) -- Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a leader in cellular metabolism and pyruvate kinase (PK) activation pioneering therapies for rare diseases, today announced that new data on the company's PK activators, mitapivat and tebapivat, will be featured in oral and poster presentations during the 30th European Hematology Association (EHA) Congress (EHA 2025) in Milan, Italy, June 12-15, 2025.
Neutral
GlobeNewsWire
1 month ago
Agios to Present at the 2025 RBC Capital Markets Global Healthcare Conference on May 21, 2025
CAMBRIDGE, Mass., May 09, 2025 (GLOBE NEWSWIRE) -- Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a leader in cellular metabolism and PK activation pioneering therapies for rare diseases, today announced that its management team is scheduled to present at the 2025 RBC Capital Markets Global Healthcare Conference on Wednesday, May 21, 2025, at 8:00 am ET.
Neutral
Zacks Investment Research
1 month ago
Agios' Q1 Loss Narrower Than Expected, Revenues Lag Estimates
AGIO's earnings beat estimates in the first quarter of 2025, while revenues miss the same.
Neutral
GlobeNewsWire
1 month ago
Agios to Present at the BofA Securities 2025 Health Care Conference on May 14, 2025
CAMBRIDGE, Mass., May 02, 2025 (GLOBE NEWSWIRE) -- Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a leader in cellular metabolism and PK activation pioneering therapies for rare diseases, today announced that its management team is scheduled to present at the BofA Securities 2025 Health Care Conference on Wednesday, May 14, 2025, at 8:00 am PT/11:00 am ET.
Neutral
Seeking Alpha
1 month ago
Agios Pharmaceuticals, Inc. (AGIO) Q1 2025 Earnings Call Transcript
Agios Pharmaceuticals, Inc. (NASDAQ:AGIO ) Q1 2025 Earnings Conference Call May 1, 2025 8:00 AM ET Company Participants Chris Taylor – Vice President-Investor Relations and Corporate Communications Brian Goff – Chief Executive Officer Sarah Gheuens – Chief Medical Officer, Head-Research and Development Tsveta Milanova – Chief Commercial Officer Cecilia Jones – Chief Financial Officer Conference Call Participants Gregory Renza – RBC Capital Markets Alec Stranahan – Bank of America Divya Rao – TD Cowen Hiro Nagayumi – Cantor Emily Bodnar – H.C. Wainwright Tessa Romero – JPMorgan Operator Good morning, and welcome to Agios' First Quarter 2025 Conference Call.
Negative
Zacks Investment Research
1 month ago
Agios Pharmaceuticals (AGIO) Reports Q1 Loss, Misses Revenue Estimates
Agios Pharmaceuticals (AGIO) came out with a quarterly loss of $1.55 per share versus the Zacks Consensus Estimate of a loss of $1.80. This compares to loss of $1.45 per share a year ago.
Neutral
GlobeNewsWire
1 month ago
Agios Reports First Quarter 2025 Financial Results and Recent Business Highlights
– U.S. Regulatory Filing Under Active Review for Approval of PYRUKYND ® (mitapivat) in Thalassemia, with PDUFA Goal Date of September 7, 2025 – – Phase 3 RISE UP Study of Mitapivat in Sickle Cell Disease On Track, with Topline Results Expected in Late 2025; Potential U.S. Commercial Launch in 2026 – – Tebapivat Advancing in Clinical Trials for Lower-Risk Myelodysplastic Syndromes (LR-MDS) and Sickle Cell Disease – – PYRUKYND Net Revenue of $8.7 Million in Q1; Cash, Cash Equivalents and Marketable Securities of $1.4 Billion as of March 31, 2025 – CAMBRIDGE, Mass., May 01, 2025 (GLOBE NEWSWIRE) -- Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a leader in cellular metabolism and pyruvate kinase (PK) activation pioneering therapies for rare diseases, today reported business highlights and financial results for the first quarter ended March 31, 2025.
Negative
Zacks Investment Research
1 month ago
Analysts Estimate Agios Pharmaceuticals (AGIO) to Report a Decline in Earnings: What to Look Out for
Agios Pharmaceuticals (AGIO) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Charts implemented using Lightweight Charts™